We're Here for You!
The IMF is dedicated to improving the quality of life of myeloma patients while working toward prevention and a cure.
There is still time to donate to help us continue to innovate our current programs and support new projects that benefit the myeloma community.
In this week’s blog, IMF Chairman of the Board and Chief Scientific Officer Dr. Brian G.M. Durie gives an overview of what’s to come during this year’s 65th American Society of Hematology (ASH) Annual Meeting and Exposition, which will take place from December 9-12, in San Diego, California, and online. With more than 7,000 accepted abstracts “representing the most cutting-edge science in hematology,” myeloma scientific content for this year’s ASH will be jampacked in sessions spanning three days—from Saturday, December 9th to Monday, December 11th. For sessions with overlapping schedules, Dr. Durie advises to use the “teamwork approach” to cover as many abstracts as possible. He makes mention of 2023’s “hot topics”—real-world data, drug access, and racial disparities—and how they will play a major part during this year’s ASH. Dr. Durie recommends enjoying the Thanksgiving break to the fullest to conserve our energies as it will definitely be a bustling few days at ASH 2023 in San Diego. READ THE BLOG.
Join us Thursday, December 14, 2023, at 11:00 a.m. PST/ 2:00 p.m. EST for the IMWG Conference Series, “Making Sense of Treatment.” Leading myeloma experts will discuss the latest myeloma research news from the 2023 American Society of Hematology (ASH) Annual Meeting and Expo.
IMF Chairman of the Board and Chief Scientific Officer Dr. Brian G.M. Durie will moderate the discussion, with Drs. María V. Mateos (University of Salamanca—Salamanca, Spain) and Thomas Martin (University of California San Francisco—San Francisco, CA) serving as panelists. REGISTER NOW.
A new clinical trial administered by the Mayo Clinic, the PragMMatic Study, is now accruing newly diagnosed multiple myeloma (NDMM) patients. Led by the IMF’s International Myeloma Working Group (IMWG) members Drs. S. Vincent Rajkumar and Shaji Kumar, the study is for the first time comparing the efficacy and side effect profiles of the three most common treatment regimens for NDMM patients. This study is currently open to those recently diagnosed with multiple myeloma who are receiving treatment for this condition. Read the full article to learn more. LEARN MORE.
Tune in as the IMF brings myeloma support group leaders and patients to the 65th annual meeting of the American Society of Hematology (ASH), “the world’s most comprehensive hematology event of the year.” Start following the IMF ASH team members now on social media as they ramp up to share the latest clinical updates in myeloma research, therapies, and practice strategies via Twitter (#ASH23 and #IMFASH23), Facebook, blogs, and videos. The IMF thanks these leaders for their care and commitment in sharing their experiences with the global myeloma community. We encourage you to visit the website and follow these leaders for their unique perspectives. EXPLORE NOW.
IMF Chief Medical Officer Dr. Joseph Mikhael along with the ASH support group leader team go live to discuss key myeloma research takeaways from the 2023 American Society of Hematology meeting and exposition. This Facebook Live Event takes place on Monday, December 11, at 7:00 p.m. PST / 10:00 p.m. EST. Visit the Facebook event page and then click ‘Going’ to register. REGISTER NOW.
Myeloma patients on Medicare: The HealthWell Foundation has opened a fund to help with co-pays/premiums. The maximum award level is $12,000, covering various treatments. Check eligibility and apply now.
Visit the IMF Financial Assistance page to view a list of links to resources that may help you find additional financial support. LEARN MORE.
Need assistance in creating a fundraiser? The IMF team is here for you. Find out how you can help in the fight against myeloma today!